Demant A/S (OTCMKTS:WILYY) Rating Lowered to Neutral at BNP Paribas

Demant A/S (OTCMKTS:WILYY – Get Rating) was downgraded by stock analysts at BNP Paribas from an “outperform” rating to a “neutral” rating in a research note issued on Wednesday, Briefing.com reports.

A number of other brokerages have also recently commented on WILYY. Credit Suisse Group cut shares of Demant A/S from a “neutral” rating to an “underperform” rating in a report on Tuesday, October 18th. Barclays increased their price target on shares of Demant A/S from 170.00 to 180.00 in a report on Tuesday, November 22nd. Morgan Stanley cut their price target on shares of Demant A/S from 191.00 to 183.00 and set an “underweight” rating for the company in a report on Monday, November 7th. Finally, Jefferies Financial Group cut shares of Demant A/S from a “buy” rating to a “hold” rating in a report on Wednesday. Four investment analysts have rated the stock with a sell rating and two have assigned a hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and an average price target of $210.75.

Demant A/S Stock Up 3.9 %

Shares of WILYY opened at $14.50 on Wednesday. Demant A/S has a 1-year low of $11.19 and a 1-year high of $23.06. The company has a debt-to-equity ratio of 0.39, a current ratio of 0.78 and a quick ratio of 0.59. The firm has a fifty day moving average price of $13.82 and a 200 day moving average price of $14.71.

Demant A/S Company Profile

(Get Rating)

Demant A/S, a hearing healthcare and audio technology company, develops, manufactures, and sells products and equipment to enhance people's hearing in Europe, North America, the Pacific, Asia, and internationally. It operates in two segments, Hearing Healthcare and Communications. The Hearing Healthcare segment offers hearing implants and aids, hearing care, and diagnostic products.